Prevalence and genotypic relatedness of carbapenem resistance among multidrug-resistant P. aeruginosa in tertiary hospitals across Thailand
© Khuntayaporn et al.; licensee BioMed Central Ltd. 2012
Received: 8 August 2012
Accepted: 9 September 2012
Published: 13 September 2012
Increased infection caused by multidrug resistant (MDR) Pseudomonas aeruginosa has raised awareness of the resistance situation worldwide. Carbapenem resistance among MDR (CR-MDR) P. aeruginosa has become a serious life-threatening problem due to the limited therapeutic options. Therefore, the objectives of this study were to determine the prevalence, the antibiotic susceptibility patterns and the relatedness of CR-MDR P. aeruginosa in tertiary hospitals across Thailand.
MDR P. aeruginosa from eight tertiary hospitals across Thailand were collected from 2007–2009. Susceptibility of P. aeruginosa clinical isolates was determined according to the Clinical and Laboratory Standards Institute guideline. Selected CR-MDR P. aeruginosa isolates were genetically analyzed by pulsed-field gel electrophoresis.
About 261 clinical isolates were identified as MDR P. aeruginosa and approximately 71.65% were found to be CR-MDR P. aeruginosa. The result showed that the meropenem resistance rate was the highest reaching over 50% in every hospitals. Additionally, the type of hospitals was a major factor affecting the resistance rate, as demonstrated by significantly higher CR-MDR rates among university and regional hospitals. The fingerprinting map identified 107 clones with at least 95% similarity. Only 4 clones were detected in more than one hospital.
Although the antibiotic resistance rate was high, the spreading of CR-MDR was found locally. Specific strains of CR-MDR did not commonly spread from one hospital to another. Importantly, clonal dissemination ratio indicated limited intra-hospital transmission in Thailand.
KeywordsAntimicrobial susceptibility Pulsed-field gel electrophoresis Carbapenem resistance Multidrug resistance Pseudomonas aeruginosa Epidemiology
Overuse of antibiotics in a hospital can cause a selective pressure on microorganisms, which in turn, can enhance the antimicrobial resistance in bacteria. Inappropriate use of antibiotics has been reported to be involved in increasing the antibiotic resistance [1, 2]. This circumstance becomes a major concern in Thailand, especially in university hospitals .
Among hospital-acquired microorganisms, Pseudomonas aeruginosa, a non-fermentative, gram-negative bacterium, is one of the most common causative agents in nosocomial infections. According to the NNISS report (National Nosocomial Infections Surveillance System in United States) and INICC (International Nosocomial Infection Control Consortium), P. aeruginosa is the most common pathogen found in intensive care units from the respiratory tract and central line-associated primary bloodstream infections [4–6]. Moreover, the report from the SENTRY program in Latin American during 1997–2000 showed that P. aeruginosa was the most commonly isolated pathogen from hospitalized pneumonia patients and had high resistance rates for most of tested antimicrobials . In Thailand, like other parts of the world, P. aeruginosa has been shown to have the highest prevalence rate along with its intrinsic antibiotic resistance mechanisms [8, 9]. Infections caused by multidrug resistant (MDR) P. aeruginosa can lead to serious outcomes such as amputation or in the worst case, death . The mortality rate of MDR P. aeruginosa infections was significantly higher than infections caused by susceptible P. aeruginosa. In the US surveillance study, MDR P. aeruginosa rate was found to increase from 4% to 14% over the period of 1993 to 2002 .
Carbapenem, a member of the β-lactam family, has a broad spectrum of activity and is stable to most β-lactamases. These properties make carbapenem to be important therapeutic options for treating serious infections involving resistant strains of Enterobacteriaceae, anaerobes, P. aeruginosa, and Acinetobacter spp. [12, 13]. Carbapenem has always been chosen as the first option for initial empirical treatment in many severe infections, e.g. nosocomial pneumonia, and chronic MDR pseudomonal infections [12, 14]. Although carbapenem is a very powerful antibiotics, the resistance rate is still increasing .
Although carbapenem resistance (CR) has been widely studied, there is limited information on the CR rates among MDR (CR-MDR) bacterial pathogens. These situations raised the question, “How many P. aeruginosa isolates in Thailand are CR-MDR?” Therefore, the objectives of this study were to determine (i) the prevalence of CR-MDR P. aeruginosa in Thailand, (ii) the antibiotic susceptibility patterns of CR-MDR P. aeruginosa, and (iii) the relatedness of CR-MDR P. aeruginosa clinical isolates across tertiary hospitals in Thailand. This study would provide the first update report on an epidemiology of CR-MDR P. aeruginosa in Thailand.
Materials and methods
P. aeruginosa clinical isolates were collected from eight hospitals from 2007 to 2009 within five regions of Thailand. The study was complied with International Guidelines for Human Research Protection and was approved by Mahidol University Institutional Review Board (MU-IRB) under the certificate of approval No. MU-IRB 2011/025.0102. All participated hospitals are tertiary hospitals. Four hospitals are regional hospitals and the other four hospitals are university hospitals. Regional hospitals located in province centers have a capacity for at least 500 beds, while university hospitals are teaching schools which also provide postgraduate and specialist programs. Both hospitals have a comprehensive set of specialists and have been transferred patients from primary and secondary hospitals in their regions. However, rare condition treatments or patients with high complexity mostly have been transferred to university hospitals. Bacterial clinical isolates were identified and performed susceptibility test by the hospital’s laboratory technicians using their standard hospital procedures. Multidrug resistance criteria in this study were defined as non-susceptible to at least 3 of 5 drug groups, including the anti-pseudomonal penicillins, cephalosporins, aminoglycosides, fluoroquinolones and carbapenem . Bacterial strains were cultured in triple sugar iron agar (BD, Sparks, MD, USA) and stored at 4°C before being submitted to the research laboratory. All bacteria clinical isolates were enriched before storage at −80°C. Cetrimide agar (BD, Sparks, MD, USA) supplement with 10% glycerol was used as the selective minimal medium to confirm isolates as P. aeruginosa.
Antibiotic susceptibility test
The susceptibility of P. aeruginosa clinical isolates was confirmed in the research laboratory by the disc diffusion method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines . All antibiotic discs in this study included piperacillin (PIP), ceftazidime (CTZ), ciprofloxacin (CIP), gentamicin (CN), imipenem (IMP), meropenem (MEM), and doripenem (DOR) were purchased from Oxoid (Hants, UK). Antibiotic discs were placed onto the inoculated Mueller Hinton agar (BD). After 37°C incubation overnight, inhibition zones were measured and compared to CLSI guidelines . Imipenem and meropenem zone diameter breakpoints were applied to doripenem since the CLSI official zone diameter breakpoints for doripenem were unavailable. Carbapenem resistance was defined by being non-susceptible to at least 1 of the 3 carbapenem tested. Among MDR P. aeruginosa clinical isolates, those that were also CR were selected for study.
Genotyping by pulsed-field Gel electrophoresis
All selected CR-MDR P. aeruginosa clinical isolates were analyzed by pulsed-field gel electrophoresis (PFGE) using CHEF Mapper XA system (Bio-Rad, Hercules, CA, USA). PFGE plugs were prepared according to Romling et al. with some modifications . The genotyping patterns were confirmed for the relatedness of bacterial isolates by Fingerprinting II InformatixTM software version 3.0 (Bio-Rad). A dendrogram was generated by the unweighted-pair group method. The correlation between band patterns was calculated with dice coefficient. Different clones were considered, if the percentage of similarity was less than 95% . The clonal dissemination ratio in each hospital was calculated by number of CR-MDR P. aeruginosa divided by number of selected clones. Selected clones found in more than one hospital were counted in every hospital. The clonal dissemination ratio was indicated intra-hospital transmission.
Statistical analysis was compared between two groups by Student t-test. A p-value of <0.05 was considered statistically significant. Data were presented as percentages unless otherwise stated.
Antimicrobial susceptibility profile
Drug resistance rates of MDR P. aeruginosa in participated hospitals
Size of Hospital
Region of Thailand
CR-MDR ratio, clonal dissemination and clone number analyzed by PFGE in participated hospitals
Size of Hospital
Region of Thailand
CR-MDR Ratio (%)
PFGE-selected clone (N)
Clonal dissemination ratio
PFGE clone number (amount of existing clones)
18 (4), 8(2), 9, 11, 15, 16, 19, 44, 69, 73, 87, 94, 95, 98, 102, 105, 106
35(9), 45(5), 53(3), 65(3), 84(3), 83(2), 86(2), 89(2),
13, 41, 46, 50, 51, 54, 56, 62, 85, 88, 99, 107
90(6), 92(3), 20(3), 26(3), 28(3), 27(2), 30(2), 68(2),
12, 14, 21, 23, 24, 25, 29, 31, 91, 93
10(3), 40(2), 41(2), 2, 17, 33, 42, 43, 52, 66, 70
5(3), 7(3), 3(2), 4(2), 55(2), 79(2), 80(2),
6, 57, 75, 76, 77, 78, 82, 97, 101, 103, 104
32(2), 81(2), 1(2), 2(2), 33, 34, 48, 49, 72, 74
62(4), 63(4), 58(2), 60(2), 64(2), 22, 39, 59, 67, 100
36 (9), 47(2), 37, 38, 41, 61, 71, 96
Pulsed-field Gel electrophoresis
The multidrug resistance of microorganisms has become the critical problem in nosocomial infections, especially P. aeruginosa and Acinetobacter spp. Both pathogens have been listed in six famous ESKAPE pathogens (Enterococcus faecium Staphylococcus aureus Klebsiella pneumoniae Acinetobacter species, Pseudomonas aeruginosa, and Enterobacter species) and identified as the most emerging threats in this century . Antimicrobial resistance surveillance, has been performed in almost every countries to identify the major problem in nosocomial infections. This study provides the first update data on the genetic relatedness of CR-MDR P. aeruginosa clinical isolates from tertiary hospitals across Thailand.
Antimicrobial resistance surveillance studies have been observed in many countries throughout the world. Most of these studies also determined carbapenem resistance rates which described higher resistance rate for imipenem than for meropenem [15, 22–24]. However, the Thailand national surveillance during 2000–2005 by Dejsirilert et al. was described in a different manner and showed a slightly greater resistance rate for meropenem than for imipenem . Moreover, a recent study which was conducted by Piyakul et al. in a tertiary hospital in Thailand indicated that P. aeruginosa clinical isolates exhibited a greater meropenem resistance rate than a rate for imipenem . In agreement with the study of Piyakul et al., our data which analyzed MDR isolates of P. aeruginosa, showed a greater difference of resistance rates between meropenem and imipenem compared to Piyakul et al.. This difference might be caused by the variety of the participated hospitals in the studies. These studies indicated that carbapenem usage in Thailand should be considered when drug susceptibility profile was unavailable.
Although the carbapenem resistance rate in P. aeruginosa or the MDR rate in P. aeruginosa is increasing, the carbepenem resistance rate among MDR strains has seldom been observed. The criteria for MDR P. aeruginosa in the study of Sekiguchi et al. which was resistant to imipenem, amikacin and ciprofloxacin was demonstrated 100% resistance rate to imipenem and meropenem and more than 90% resistance to arbekacin, doripenem, and aztreonam. Only resistances to polymyxin B and gentamicin were found to be significantly lower, at about 28% and 57.5%, respectively . According to MDR criteria in this study which was less stringent, antibiotic resistance rates of MDR P. aeruginosa were higher than 50% for most antibiotics. Only doripenem susceptibility was found to be more than 60%. This lower resistance rate might be because doripenem was recently approved for use in Thailand. Interestingly, the overall resistance rate of MDR P. aeruginosa in Thailand was found quite high. These situations could urge an awareness of limit antibiotic usage. Only recent launched antibiotic, doripenem, was showed the resistance rate less than 40%. Thus, highly concern should be recommended especially in the strategy to prevent drug resistance emerging and to preserve sensitivity of present antibiotics.
MDR P. aeruginosa is a life-threatening problem that limits the use of critical antibiotics for treatment. The ratio of CR-MDR among MDR isolated was very high in hospitals, especially the university hospitals. The results of the present study indicated that those hospitals, which handled more complicated cases and thus employed more complicated antibiotic treatments, could develop more complicated drug resistance problems. Moreover, inappropiate consumption of antibiotics has been a concern in tertiary care hospitals and especially university hospitals in Thailand . High amounts of drug consumption in a hospital can cause a selective pressure on microorganisms resulting in increased drug resistance . This study reported significantly higher rate of CR-MDR P. aeruginosa in university hospitals than regional hospitals. Correlated with the study of Danchaivijitr et al., the data showed that university hospitals had greater consumption of carbapenem than regional hospitals .
It was noteworthy that a single resistance of doripenem in CR-MDR P. aeruginosa was not detected in this study. This finding was correlated to lower MIC of doripenem compared to other carbapenem . The doripenem single resistance could be explained by the fact that this drug was newly introduced to Thailand. This data implied that resistance mechanisms for doripenem have not yet been fully acquired by multidrug resistant strains. Moreover, double resistance of imipenem and doripenem was found in only one strain as compared to double resistance of meropenem and doripenem which could be detected in twenty-five strains. The well-known resistance mechanisms of carbapenem such as loss of porins, increasing of efflux systems and enzyme degradation, were also reported to affect doripenem . Metallo-beta-lactamases were reported to affect all carbapenem, but imipenem and meropenem had different response to loss of oprD and efflux pump overexpression . Increasing the efflux pumps could mainly affect both meropenem and doripenem, but not imipenem [29, 30]. However, some doripenem-resistant P. aeruginosa clinical isolates have been found to lack functional OprD . The multiple resistances of CR-MDR P. aeruginosa suggested the possible use of polymyxin for treatment. Although polymyxin remains active on the CD-MDR strains, polymyxin is a drug with high nephrotoxic side effect . Our data suggested that treatment with doripenem might be an optional treatment instead of polymyxin to avoid side effect.
The PFGE results demonstrated a multiple DNA patterns among the resistant strains . One hundred and seven clones were identified from 218 clinical isolates indicating remarkable clonal diversity. Only 4 from 107 different clones were found to be inter-hospital transmission. Two from four clones were detected in the same region and only two clones were found in different regions. Because of the difficulty in accessing patient histories, the method of transmission between hospitals could not be determined. There was a possibility that infected patients were transferred between the hospitals. The clonal dissemination ratio showed limited of inter-hospital transmission. The ratio of higher than 2.0 was found in two hospitals indicating that one clone was infected in more than two patients. Additionally, these hospitals were found dominant clones at about 9 isolates per clone as showed in the Table 2. For other six hospitals, the clonal dissemination showed that each patient was infected by different clones indicating high variation of CR-MDR P. aeruginosa. It was possible that high consumption of antibiotic usage could provide high pressure condition inducing mutation in bacteria.
The available results indicated that the high resistance rate of MDR P. aeruginosa was localized and was due to the antibiotic selection pressure. Antibiotic usage should be carefully evaluated for its effect on the development of bacterial resistance. Infectious Diseases Society of America (IDSA) has presented guidelines for developing an institutional program to enhance antibiotic stewardship . The aim of the guidelines is to optimize antibiotic selection and usage while maximize the clinical outcomes. Since our results indicated that Thailand might have some patterns of resistance different from that of other countries. Therapeutic options in Thailand should be considered and adapted to minimize our resistance problems. An appropriate adjustment of antibiotic usage should reduce the emergence of antibiotic resistance microorganisms and also can preserve the existing and future antimicrobial agents [33, 34].
Because CR-MDR P. aeruginosa infections are frequently life-threatening, strategies to control the spreading of antibiotic resistance phenomenon are necessary. Our results showed that the spreading of CR-MDR in Thailand was local, but the resistance rate of these strains was high. The high consumption of antibiotics might be a major problem. Therefore, antibiotic stewardship is one of the strategies that might help resolve the problems. The effective strategies to control the mutation of bacterial resistance are required to prevent the spreading and also antibiotic strategy for treatment.
The authors wish to thank Professor Richard J. O’Callaghan for critical comments on the manuscript. Financial support from the Thailand Research Fund and Mahidol University through the RGJ-Ph.D. Program (Grant No. PHD/0062/2550) to Piyatip Khuntayaporn and Mullika Chomnawang, and the Thailand Research Fund (Grant No. DBG5380041) are acknowledged. The authors wish to thank Assoc. Prof. Dr. Pattarachai Kiratisin at Faculty of Medicine Siriraj Hospital, Umnaj Chanama and Chanikarn Boonchoy at Institute of Molecular Biosciences, Mahidol University for their PFGE technique support. We also thanks Jiraporn Nilsakul, Manasanant Bunchoo, Parichart Thunyathada, Sujitra Manakul, Surapee Tiengrim, Thanaporn Hortiwakul, and Watcharee Joraka for their help in bacterial collections.
- Mohammadtaheri Z, Pourpaki M, Mohammadi F, Namdar R, Masjedi MR: Surveillance of antimicrobial susceptibility among bacterial isolates from intensive care unit patients of a tertiary-care university hospital in Iran: 2006–2009. Chemotherapy. 2010, 56 (6): 478-484. 10.1159/000321032View ArticlePubMed
- Isturiz RE, Carbon C: Antibiotic use in developing countries. Infect Control Hosp Epidemiol. 2000, 21 (6): 394-397. 10.1086/501780View ArticlePubMed
- Rattanaumpawan P, Sutha P, Thamlikitkul V: Effectiveness of drug use evaluation and antibiotic authorization on patients’ clinical outcomes, antibiotic consumption, and antibiotic expenditures. Am J Infect Control. 2010, 38 (1): 38-43. 10.1016/j.ajic.2009.04.288View ArticlePubMed
- Obritsch MD, Fish DN, MacLaren R, Jung R: National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004, 48 (12): 4606-4610. 10.1128/AAC.48.12.4606-4610.2004View ArticlePubMedPubMed Central
- Gaynes R, Edwards JR: Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005, 41 (6): 848-854. 10.1086/432803View ArticlePubMed
- Rosenthal VD, Maki DG, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, Leblebicioglu H, Abu Khader I, Miranda Novales MG, Berba R: International nosocomial infection control consortium (INICC) report, data summary for 2003–2008, issued June 2009. Am J Infect Control. 2010, 38 (2): 95-104. e102, 10.1016/j.ajic.2009.12.004View ArticlePubMed
- Gales AC, Sader HH, Jones RN: Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in latin america: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY antimicrobial surveillance program (1997–2000). Diagn Microbiol Infect Dis. 2002, 44 (3): 301-311. 10.1016/S0732-8893(02)00499-6View ArticlePubMed
- Danchaivijitr S, Judaeng T, Sripalakij S, Naksawas K, Plipat T: Prevalence of nosocomial infection in Thailand 2006. J Med Assoc Thai. 2007, 90 (8): 1524-1529.PubMed
- Strateva T, Yordanov D: Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol. 2009, 58 (Pt 9): 1133-1148.View ArticlePubMed
- Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y: Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis. 1999, 28 (5): 1128-1133. 10.1086/514760View ArticlePubMed
- Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A, Tsaganos T, Kanellakopoulou K, Giamarellou H: Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int J Antimicrob Agents. 2006, 27 (6): 476-481. 10.1016/j.ijantimicag.2005.12.013View ArticlePubMed
- Kattan JN, Villegas MV, Quinn JP: New developments in carbapenems. Clin Microbiol Infect. 2008, 14 (12): 1102-1111. 10.1111/j.1469-0691.2008.02101.xView ArticlePubMed
- Walsh TR: Clinically significant carbapenemases: an update. Curr Opin Infect Dis. 2008, 21 (4): 367-371. 10.1097/QCO.0b013e328303670bView ArticlePubMed
- Masterton RG: The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents. 2009, 33 (2): 105-110.View ArticlePubMed
- Baumgart AM, Molinari MA, Silveira AC: Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis. 2010, 14 (5): 433-436. 10.1590/S1413-86702010000500002View ArticlePubMed
- Falagas ME, Koletsi PK, Bliziotis IA: The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol. 2006, 55 (Pt 12): 1619-1629.View ArticlePubMed
- Clinical and Laboratory Standard Institute: Performance standards for antimicrobial disk susceptibility tests. Approved standard - Tenth edition, CLSI document M02-A10. 2009, PA, USA: Wayne,
- Clinical and Laboratory Standards Institute: Twenty-first informational supplement, CLSI document M100-S21. Performance standards for antimicrobial susceptibility testing. 2011, PA, USA: Wayne,
- Romling U, Wingender J, Muller H, Tummler B: A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl Environ Microbiol. 1994, 60 (6): 1734-1738.PubMedPubMed Central
- Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B: Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995, 33 (9): 2233-2239.PubMedPubMed Central
- Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48 (1): 1-12. 10.1086/595011View ArticlePubMed
- Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC: SENTRY antimicrobial surveillance program report: latin american and brazilian results for 1997 through 2001. Braz J Infect Dis. 2004, 8 (1): 25-79. 10.1590/S1413-86702004000100004View ArticlePubMed
- Wang J, Zhou JY, Qu TT, Shen P, Wei ZQ, Yu YS, Li LJ: Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int J Antimicrob Agents. 2010, 35 (5): 486-491. 10.1016/j.ijantimicag.2009.12.014View ArticlePubMed
- Ho J, Tambyah PA, Paterson DL: Multiresistant gram-negative infections: a global perspective. Curr Opin Infect Dis. 2010, 23 (6): 546-553. 10.1097/QCO.0b013e32833f0d3eView ArticlePubMed
- Dejsirilert S, Suankratay C, Trakulsomboon S, Thongmali O, Sawanpanyalert P, Aswapokee N, Tantisiriwat W: National antimicrobial resistance surveillance, thailand (NARST) data among clinical isolates of pseudomonas aeruginosa in thailand from 2000 to 2005. J Med Assoc Thai. 2009, 92 (Suppl 4): S68-S75.PubMed
- Piyakul C, Tiyawisutsri R, Boonbumrung K: Emergence of metallo-beta-lactamase IMP-14 and VIM-2 in Pseudomonas aeruginosa clinical isolates from a tertiary-level hospital in Thailand. Epidemiol Infect. 2012, 140 (3): 539-541. 10.1017/S0950268811001294View ArticlePubMed
- Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Kasai A, Mizuguchi Y, Araake M, Fujino T, Kikuchi H, Sasaki S, Watari H: Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J Clin Microbiol. 2007, 45 (3): 979-989. 10.1128/JCM.01772-06View ArticlePubMedPubMed Central
- Fritsche TR, Stilwell MG, Jones RN: Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect. 2005, 11 (12): 974-984. 10.1111/j.1469-0691.2005.01271.xView ArticlePubMed
- Alvarez-Lerma F, Grau S, Ferrandez O: Characteristics of doripenem: a new broad-spectrum antibiotic. Drug Des Devel Ther. 2009, 3: 173-190.View ArticlePubMedPubMed Central
- Matthews SJ, Lancaster JW: Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther. 2009, 31 (1): 42-63. 10.1016/j.clinthera.2009.01.013View ArticlePubMed
- Mushtaq S, Ge Y, Livermore DM: Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother. 2004, 48 (8): 3086-3092. 10.1128/AAC.48.8.3086-3092.2004View ArticlePubMedPubMed Central
- Sarkar S, DeSantis ER, Kuper J: Resurgence of colistin use. Am J Health Syst Pharm. 2007, 64 (23): 2462-2466. 10.2146/ajhp060501View ArticlePubMed
- Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF: Infectious diseases society of america and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007, 44 (2): 159-177. 10.1086/510393View ArticlePubMed
- Tamma PD, Cosgrove SE: Antimicrobial stewardship. Infect Dis Clin North Am. 2011, 25 (1): 245-260. 10.1016/j.idc.2010.11.011View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.